Anti-interferon-γ antibodies in the treatment of autoimmune diseases

Current Opinion in Molecular Therapeutics

Volumn 5, Issue 1, 2003, Pages 52-57

  Skurkovich, Boris ^a   Skurkovich, Simon ^b  

^a BROWN UNIVERSITY   (United States)

^b Advanced Biotherapy   (United States)

Author keywords

Anticytokine therapy; Autoimmune disease; Clinical investigation; Cytokines; Interferon

Indexed keywords

ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; GAMMA INTERFERON ANTIBODY; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN G; INFLIXIMAB; INSULIN; INTERFERON ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 6 ANTIBODY; PLACEBO; PREDNISOLONE; STEROID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VITAMIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALOPECIA AREATA; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; CLINICAL FEATURE; CLINICAL TRIAL; CORNEA TRANSPLANTATION; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; EPIDERMOLYSIS BULLOSA; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HELPER CELL; HUMAN; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; INTERFERON PRODUCTION; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; PEMPHIGUS VULGARIS; PROTEIN TARGETING; PSORIASIS VULGARIS; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; SKIN DISEASE; UVEITIS; VIRUS INFECTION; VITILIGO;

ANIMALS; ANTIBODIES; AUTOIMMUNE DISEASES; HUMANS; INTERFERON TYPE II; TREATMENT OUTCOME;

BACTERIA (MICROORGANISMS); PEMPHIGUS;

EID: 0037300753     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Skurkovich SV, Klinova EG, Eremkina EI, Levina NV: Immunosuppressive effect of an anti-interferon serum. Nature (1974) 247(442):551-552.
2. Skurkovich SV, Klinova EG, Aleksandrovskaya IM, Levina NV, Arkhipova NA, Bulicheva TI: Stimulation of transplantation immunity and plasma cell reaction by interferon in mice. Immunology (1973) 25(2):317-322.
3. Skurkovich S, Skurkovich B: The role of interferon in the development of ADs and allergy (immediate hypersensitivity). Third Annual International Congress on Interferon Research (1982).
4. Skurkovich S, Skurkovich B, Bellanti JA: A unifying model of the immunoregulatory role of the interferon system: Can interferon produce disease in humans? Clin Immunol Immunopathol (1987) 43(3):362-373.
5. Skurkovich SV, Skurkovich B: Development of autoimmune disease is connected with the initial disturbance of IFN synthesis in the cells. J Interferon Res (1989) 9:S2.
6. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J et al: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumour necrosis factor-α. Arthritis Rheum (1993) 36(12):1681-1690.
7. Abuzakouk M, Feighery C, Jackson J: Tumour necrosis factor blocking agents: A new therapeutic modality for inflammatory disorders. Br J Biomed Sci (2002) 59(3):173-179.
8. Firestein GS, Zvaifler NJ: Anti-cytokine therapy in rheumatoid arthritis. N Engl J Med (1997) 337(3):195-197.
9. Menghini VV, Arora AS: Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc (2001) 76(1):84-86.
10. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM: Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med (2001) 345(15):1098-1104.
11. Snapper C: Interferon-γ. In: Cytokine Regulation of Humoral Immunity. Snapper C (Ed), Wiley & Sons, New York, NY, USA (1996):325.
12. Farrar MA, Schreiber RD: The molecular cell biology of interferon-γ and its receptor. Annu Rev Immunol (1993) 11:571-611.
13. Munoz-Fernandez MA, Fresno M: The role of tumour necrosis factor, interleukin 6, interferon-γ and inducible nitric oxide synthase in the development and pathology of the nervous system. Prog Neurobiol (1998) 56(3):307-340.
14. Strigard K, Holmdahl R, van der Meide PH, Klareskog L, Olsson T: In vivo treatment of rats with monoclonal antibodies against γ-interferon: Effects on experimental allergic neuritis. Acta Neurol Scand (1989) 80(3):201-207.
15. Tang H, Mignon-Godefroy K, Meroni PL, Garotta G, Charreire J, Nicoletti F: The effects of a monoclonal antibody to interferon-γ on experimental autoimmune thyroiditis (EAT): Prevention of disease and decrease of EAT-specific T-cells. Eur J Immunol (1993) 23(1):275-278.
16. Jacob CO: In vivo treatment of (NZB × NZW)F1 lupus-like nephritis with monoclonal antibody to γ-interferon. J Exp Med (1987) 166(3):798-803.
17. Debray-Sachs M, Carnaud C, Boitard C, Cohen H, Gresser I, Bedossa P, Bach JF: Prevention of diabetes in NOD mice treated with antibody to murine IFNγ. J Autoimmun (1991) 4(2):237-248.
18. Nicoletti F, Meroni PL, Landolf S, Gariglio M, Guzzardi S, Barcellini W, Lunetta M, Mughini L, Zanussi C: Prevention of diabetes in BB/Wor rats treated with monoclonal antibodies to interferon-γ. Lancet (1990) 336(8710):319.
19. Conlon KC, Urba WJ, Smith JW II, Steis RG, Longo DL, Clark JW: Exacerbation of symptoms of autoimmune disease in patients receiving α-interferon therapy. Cancer (1990) 65(10):2237-2242.
20. Ronnblom LE, Alm GV, Oberg KE: Autoimmunity after α-interferon therapy for malignant carcinoid tumors. Ann Intern Med (1991) 115(3):178-183.
21. Skurkovich SV, Loukina GV, Sigidin YA, Skurkovich BS: Successful first-time use of antibodies to interferon-γ alone and combined with antibodies to tumor necrosis factor-α to treat rheumatic diseases (rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, Behcet's syndrome). Int J Immunother (1998) 14:23-32.
22. Sigidin YA, Loukina GV, Skurkovich B, Skurkovich S: Randomized, double-blind trial of anti-interferon-γ antibodies in rheumatoid arthritis. Scand J Rheumatol (2001) 30(4):203-207.
23. Loukina G, Sigidin Ya, Pushkova O, Skurkovich B, Skurkovich S: Immunotherapy of acute rheumatoid arthritis (double-blind, placebo-controlled study using anti-IFNγ and anti-TNFα antibodies). Clin Immunol (2002) 103(S106):Abs 322.
24. Skurkovich SV, Skorikova AS, Dubrovina NA, Riabova TV, Eremkina EI, Golodnenkova VN, Klinova EG, Olshanski AJ, Shurlapova NF: Lymphocytes' cytotoxicity towards cells of human lymphoblastoid lines in patients with rheumatoid arthritis and systemic lupus erythematosus. Ann Allergy (1977) 39(5):344-350.
25. Skurkovich S, Boiko A, Beliaeva I, Buglak A, Alekseeva T, Smirnova N, Kulakova O, Tchechonin V, Gurova O, Deomina T, Favorova OO et al: Randomized study of antibodies to IFNγ and TNFα in secondary progressive multiple sclerosis. Multiple Sclerosis (2001) 7(5):277-284.
26. Sano Y, Osawa H, Sotozono C, Kinoshita S: Cytokine expression during orthotopic allograft rejection in mice. Invest Ophthalmol Vis Sci (1998) 39(10):1953-1957.
27. Sit M, Weisbrod DJ, Naor J, Slomovic AR: Corneal graft outcome study. Cornea (2001) 20(2):129-133.
28. King WJ, Comer RM, Hudde T, Larkin DF, George AJ: Cytokine and chemokine expression kinetics after corneal transplantation. Transplantation (2000) 70(8):1225-1233.
29. Skurkovich SV, Kasparov A, Narbut N, Skurkovich B: Treatment of corneal transplant rejection in humans with anti-interferon-γ antibodies. Am J Opthalmol (2002) 133(6):829-830.
30. McElwee KJ, Tobin DJ, Bystryn JC, King LE Jr, Sundberg JP: Alopecia areata: An autoimmune disease? Exp Dermatol (1999) 8(5):371-379.
31. Valdimarsson H, Baker BS, Jonsdottir I, Powles A, Fry L: Psoriasis: A T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol Today (1995) 16(3):145-149.
32. Kemp EH, Waterman EA, Weetman AP: Autoimmune aspects of vitiligo. Autoimmunity (2001) 34(1):65-77.
33. Hoffmann R: The potential role of cytokines and T-cells in alopecia areata. J Invest Dermatol Symp Proc (1999) 4(3):235-238.
34. Brown DW, Baker BS, Ovigne JM, Hardman C, Powles AV, Fry L: Skin CD4+ T-cells produce interferon-γ in vitro in response to streptococcal antigens in chronic plaque psoriasis. J Invest Dermatol (2000) 114(3):576-580.
35. Lang KS, Caroli CC, Muhm A, Wernet D, Moris A, Schittek B, Knauss-Scherwitz E, Stevanovic S, Rammensee HG, Garbe C: HLA-A2 restricted, melanocyte-specific CD8+ T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. J Invest Dermatol (2001) 116(6):891-897.
36. Skurkovich S, Korotky NG, Sharova NM, Skurkovich B: Successful anti-IFNγ therapy of alopecia areata, vitiligo, and psoriasis. Clin Immunol (2002) 103(S103):Abs 311.
37. Skurkovich S, Korotky NG, Sharova NM, Skurkovich B: Successful anti-interferon-γ therapy of alopecia areata, vitiligo, and psoriasis vulgaris (new approach to treating Th-1 autoimmune diseases). Fifth Asia Pacific Congress of Allergology and Clinical Immunology/Seventh West Pacific Allergy Symposium (2002):Abs FP4-5.
38. Skurkovich SV, Aleksandrovsky YA, Chekhonin VP, Ryabukhin IA, Chakhava KO, Skurkovich B: Improvement in negative symptoms of schizophrenia with antibodies to tumor necrosis factor-α and to interferon-γ (case study). J Clin Psychiatry (2003):in press.
39. Karlsson H, Bachmann S, Schroder J, McArthur J, Torrey EF, Yolken RH: Retroviral RNA identified in the cerebrospinal fluids and brains of individuals with schizophrenia. Proc Natl Acad Sci USA (2001) 98(8):4634-4639.
40. Christensen T, Sorensen PD, Hansen HJ, Moller-Larsen A: Endogenous retroviruses in multiple sclerosis. Ugeskr Laeger (2001) 163(3):297-301.
41. MacKay IR: Psoriasis, psoriatic arthritis. In: The Autoimmune Diseases, 3rd Edition. Rose NR, Mackay IR (Eds), Academic Press, New York, NY, USA (1998):772.
42. Abbas AK, Lichtman AH, Pober JS: Cellular and Molecular Immunology, 4th Edition. WB Saunders, Philadelphia, PA, USA (2000).
43. Asadullah K, Sterry W, Stephanek K, Jasulaitis D, Leupold M, Audring H, Volk HD, Docke WD: IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: A new therapeutic approach. J Clin Invest (1998) 101(4):783-794.
44. Toungouz M, Denys C, Andrien M, De Groote D, Dupont E: Interleukin-12 unmasks HLA class I differences during mixed lymphocyte reaction induced interferon-γ production. Hum Immunol (1995) 44(3):145-155.
45. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB: Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial. Lancet (2001) 357(9271):1842-1847.
46. Revel M, Chebath J, Mangelus M, Harroch S, Moviglia GA: Antagonism of interferon-β on interferon-γ: Inhibition of signal transduction in vitro and reduction of serum levels in multiple sclerosis patients. Multiple Sclerosis (1995) 1(Suppl 1):S5-S11.
47. Hayes CE: Vitamin D: A natural inhibitor of multiple sclerosis. Proc Nutr Soc (2000) 59(4):531-535.
48. Staeva-Vieira TP, Freedman LP: 1,25-Dihydroxyvitamin D3 inhibits IFNγ and IL-4 levels during in vitro polarization of primary murine CD4+ T-cells. J Immunol (2002) 168(3):1181-1189.
49. Prud'homme GJ, Lawson BR, Theofilopoulos AN: Anticytokine gene therapy of autoimmune diseases. Exp Opin Biol Ther (2001) 1(3):359-373.
50. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O'Connor PW: A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med (2003) 348(1):15-23.
51. O'Dell JR: Anticytokine therapy - A new era in the treatment of rheumatoid arthritis? N Engl J Med (1999) 340(4):310-312.
52. Hamers R, Muyldermans S: Immunology of camels and llamas. In: Handbook of Vertebrate Immunology. Pastoret P-P, Griebel P, Bazin H, Govaerts A (Eds), Academic Press, London, UK (1998):434-435.